Nevirapine - PMC

Result Filters

You searched 8+ million full text articles

Try this search in 34+ million citations and abstracts

PMC Full-Text Search Results

Items: 1 to 20 of 15510

<< First< Prev

Page of 776

Next >Last >>

Select item 79462831.

Effects of the Pratt pouch model of dispensing nevirapine prophylaxis on HIV exposed infant completion of 6 weeks of prophylaxis in Uganda

Edward Bitarakwate, Kim Ashburn, Patrick Kazooba, Ronald Khamasi, Eliab Natumanya, Nicole Herrera, Boaz Owomugisha, Robert A. Malkin, Linda Kisaakye

PLoS One. 2021; 16(3): e0247507. Published online 2021 Mar 10. doi: 10.1371/journal.pone.0247507

PMCID:: PMC7946283

Abstract Article PDF–1.0M

Select item 67615072.

Effect of First-Line Antituberculosis Therapy on Nevirapine Pharmacokinetics in Children Younger than Three Years Old

Anthony Enimil, Sampson Antwi, Hongmei Yang, Albert Dompreh, Wael A. Alghamdi, Fizza S. Gillani, Antoinette Orstin, Dennis Bosomtwe, Theresa Opoku, Jennifer Norman, Lubbe Wiesner, Taimour Langaee, Charles A. Peloquin, Michael H. Court, David J. Greenblatt, Awewura Kwara

Antimicrob Agents Chemother. 2019 Oct; 63(10): e00839-19. Prepublished online 2019 Jul 22. Published online 2019 Sep 23. doi: 10.1128/AAC.00839-19

PMCID:: PMC6761507

Abstract Article PDF–1.0M

Select item 76556263.

Pharmacogenetic Interactions of Rifapentine plus Isoniazid with Efavirenz or Nevirapine

David W. Haas, Anthony T. Podany, Yajing Bao, Susan Swindells, Richard E. Chaisson, Noluthando Mwelase, Khuanchai Supparatpinyo, Lerato Mohapi, Amita Gupta, Constance A. Benson, Paxton Baker, Courtney V. Fletcher, AIDS Clinical Trials Group A5279 Study Team

Pharmacogenet Genomics. Author manuscript; available in PMC 2022 Jan 1.

Published in final edited form as: Pharmacogenet Genomics. 2021 Jan; 31(1): 17–27. doi: 10.1097/FPC.0000000000000417

PMCID:: PMC7655626

Abstract Article PDF–1.2M

Select item 63792144.

Pharmacogenetics of artemether‐lumefantrine influence on nevirapine disposition: Clinically significant drug–drug interaction?

Sa'ad T. Abdullahi, Adeniyi Olagunju, Julius O. Soyinka, Rahman A. Bolarinwa, Olusola J. Olarewaju, Moji T. Bakare‐Odunola, Andrew Owen, Saye Khoo

Br J Clin Pharmacol. 2019 Mar; 85(3): 540–550. Published online 2019 Jan 2. doi: 10.1111/bcp.13821

PMCID:: PMC6379214

Abstract Article PDF–2.2M

Select item 60321955.

Interaction of Nevirapine with the Peptide Binding Groove of HLA-DRB1*01:01 and Its Effect on the Conformation of HLA-Peptide Complex

Makoto Hirasawa, Katsunobu Hagihara, Koji Abe, Osamu Ando, Noriaki Hirayama

Int J Mol Sci. 2018 Jun; 19(6): 1660. Published online 2018 Jun 4. doi: 10.3390/ijms19061660

PMCID:: PMC6032195

Abstract Article PDF–2.5M

Select item 70382756.

Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by CYP2B6 c.516G>T Genotypes

Sa’ad T. Abdullahi, Julius O. Soyinka, Adeniyi Olagunju, Rahman A. Bolarinwa, Olusola J. Olarewaju, Moji T. Bakare-Odunola, Markus Winterberg, Joel Tarning, Andrew Owen, Saye Khoo

Antimicrob Agents Chemother. 2020 Mar; 64(3): e00947-19. Prepublished online 2019 Dec 23. Published online 2020 Feb 21. doi: 10.1128/AAC.00947-19

PMCID:: PMC7038275

Abstract Article PDF–822K

Select item 79330837.

Early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: pharmacokinetics and safety data from a Phase I/II Proof of Concept Study

Theodore D Ruel, Edmund V. Capparelli, Camlin Tierney, Bryan S. Nelson, Anne Coletti, Yvonne Bryson, Mark F. Cotton, Stephen A. Spector, Mark Mirochnick, Rebecca LeBlanc, Christina Reding, Bonnie Zimmer, Deborah Persaud, Mutsa Bwakura-Dangarembizi, Kimesh L Naidoo, Rohan Hazra, Patrick Jean-Philippe, Ellen G. Chadwick

Lancet HIV. Author manuscript; available in PMC 2022 Mar 1.

Published in final edited form as: Lancet HIV. 2021 Mar; 8(3): e149–e157. Published online 2020 Nov 23. doi: 10.1016/S2352-3018(20)30274-5

PMCID:: PMC7933083

Abstract Article PDF–411K

Select item 68854428.

Nevirapine inhibits migration and invasion in dedifferentiated thyroid cancer cells

Hongxia Shang, Junyu Zhao, Jinming Yao, Huanjun Wang, Shengnan Wang, Jianjun Dong, Lin Liao

Thorac Cancer. 2019 Dec; 10(12): 2243–2252. Published online 2019 Oct 21. doi: 10.1111/1759-7714.13211

PMCID:: PMC6885442

Abstract Article PDF–8.9M

Select item 78791409.

Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention

A T Podany, J Leon-Cruz, J Hakim, K Supparatpinyo, A Omoz-Oarhe, D Langat, N Mwelase, C Kanyama, A Gupta, C A Benson, R E Chaisson, S Swindells, C V Fletcher, the AIDS Clinical Trials Group A5279 Team

J Antimicrob Chemother. 2021 Mar; 76(3): 718–721. Published online 2020 Nov 30. doi: 10.1093/jac/dkaa470

PMCID:: PMC7879140

Abstract Article PDF–144K

Select item 540009110.

Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population

Daniel F. Carr, Stephane Bourgeois, Mas Chaponda, Louise Y. Takeshita, Andrew P. Morris, Elena M. Cornejo Castro, Ana Alfirevic, Andrew R. Jones, Daniel J. Rigden, Sam Haldenby, Saye Khoo, David G. Lalloo, Robert S. Heyderman, Collet Dandara, Elizabeth Kampira, Joep J. van Oosterhout, Francis Ssali, Paula Munderi, Giuseppe Novelli, Paola Borgiani, Matthew R. Nelson, Arthur Holden, Panos Deloukas, Munir Pirmohamed

J Antimicrob Chemother. 2017 Apr; 72(4): 1152–1162. Published online 2017 Jan 5. doi: 10.1093/jac/dkw545

PMCID:: PMC5400091

Abstract Article PDF–653K

Select item 556518711.

Sub-therapeutic nevirapine concentration during antiretroviral treatment initiation among children living with HIV: Implications for therapeutic drug monitoring

Bindu Parachalil Gopalan, Kayur Mehta, Reena R. D'souza, Niharika Rajnala, Hemanth Kumar A. K., Geetha Ramachandran, Anita Shet

PLoS One. 2017; 12(8): e0183080. Published online 2017 Aug 21. doi: 10.1371/journal.pone.0183080

PMCID:: PMC5565187

Abstract Article PDF–905K

Select item 534889012.

Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study

Tsitsi G. Monera-Penduka, Charles C. Maponga, Alan R. Wolfe, Lubbe Wiesner, Gene D. Morse, Charles F. B. Nhachi

AIDS Res Ther. 2017; 14: 12. Published online 2017 Mar 14. doi: 10.1186/s12981-017-0140-4

PMCID:: PMC5348890

Abstract Article PDF–967K

Select item 589068313.

Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants

Helen McIlleron, Paolo Denti, Silvia Cohn, Fildah Mashabela, Jennifer D. Hoffmann, Saba Shembe, Regina Msandiwa, Lubbe Wiesner, Sithembiso Velaphi, Sanjay G. Lala, Richard E. Chaisson, Neil Martinson, Kelly E. Dooley, on behalf of the Tshepiso Study Team

J Antimicrob Chemother. 2017 Jul; 72(7): 2028–2034. Published online 2017 Apr 16. doi: 10.1093/jac/dkx112

PMCID:: PMC5890683

Abstract Article PDF–281K

Select item 438148414.

Evaluation of adherence measures of antiretroviral prophylaxis in HIV exposed infants in the first 6 weeks of life

Alicia Catherine Desmond, Dhayendre Moodley, Catherine A Conolly, Sandra A Castel, Hoosen M Coovadia

BMC Pediatr. 2015; 15: 23. Published online 2015 Mar 19. doi: 10.1186/s12887-015-0340-9

PMCID:: PMC4381484

Abstract Article PDF–412K

Select item 731242915.

Nevirapine Biotransformation Insights: An Integrated In Vitro Approach Unveils the Biocompetence and Glutathiolomic Profile of a Human Hepatocyte-Like Cell 3D Model

Madalena Cipriano, Pedro F Pinheiro, Catarina O Sequeira, Joana S Rodrigues, Nuno G Oliveira, Alexandra M M Antunes, Matilde Castro, M Matilde Marques, Sofia A Pereira, Joana P Miranda

Int J Mol Sci. 2020 Jun; 21(11): 3998. Published online 2020 Jun 3. doi: 10.3390/ijms21113998

PMCID:: PMC7312429

Abstract Article PDF–2.6M

Select item 553321316.

Virologic Response to First-Line Efavirenz- or Nevirapine-Based Anti-Retroviral Therapy in HIV-Infected African Children

Adeodata Kekitiinwa, Alexander J. Szubert, Moira Spyer, Richard Katuramu, Victor Musiime, Tawanda Mhute, Sabrina Bakeera-Kitaka, Oscar Senfuma, Ann Sarah Walker, Diana M Gibb, for the ARROW Trial Team

Pediatr Infect Dis J. Author manuscript; available in PMC 2018 Jun 1.

Published in final edited form as: Pediatr Infect Dis J. 2017 Jun; 36(6): 588–594. doi: 10.1097/INF.0000000000001505

PMCID:: PMC5533213

Abstract Article PDF–321K

Select item 457553817.

Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients

Doreen Mhandire, Miguel Lacerda, Sandra Castel, Kudakwashe Mhandire, Danai Zhou, Marelize Swart, Tinei Shamu, Peter Smith, Tutsirai Musingwini, Lubbe Wiesner, Babill Stray-Pedersen, Collet Dandara

OMICS. 2015 Sep 1; 19(9): 553–562. doi: 10.1089/omi.2015.0104

PMCID:: PMC4575538

Abstract Article PDF–268K

Select item 675348418.

Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART

Megan Neary, Catherine A Chappell, Kimberly K Scarsi, Shadia Nakalema, Joshua Matovu, Sharon L Achilles, Beatrice A Chen, Marco Siccardi, Andrew Owen, Mohammed Lamorde

J Antimicrob Chemother. 2019 Oct; 74(10): 3003–3010. Published online 2019 Jul 12. doi: 10.1093/jac/dkz298

PMCID:: PMC6753484

Abstract Article PDF–254K

Select item 883061919.

Nevirapine hair and plasma concentrations and HIV-1 viral suppression among HIV infected ante-partum and post-partum women attended in a mother and child prevention program in Maputo city, Mozambique

Rosa Marlene Cuco, Osvaldo Loquiha, Adelino Juga, Aleny Couto, Bindiya Meggi, Adolfo Vubil, Esperança Sevene, Nafissa Osman, Marleen Temermam, Olivier Degomme, Mohsin Sidat, Nilesh Bhatt

PLoS One. 2022; 17(2): e0261522. Published online 2022 Feb 10. doi: 10.1371/journal.pone.0261522

Correction in:: PLoS One. 2023; 18(1): e0281190.

PMCID:: PMC8830619

Abstract Article PDF–1022K

Select item 858594220.

Association between social psychological status and efavirenz and nevirapine plasma concentration among HIV patients in Kenya

Musa Otieno Ngayo, Margaret Oluka, Wallace Dimbuson Bulimo, Faith Apolot Okalebo

Sci Rep. 2021; 11: 22071. Published online 2021 Nov 11. doi: 10.1038/s41598-021-01345-9

PMCID:: PMC8585942

Abstract Article PDF–1.2M

<< First< Prev

Page of 776

Next >Last >>

Supplemental Content

Filter your results:

Manage Filters

PMC Images search for Nevirapine

Figure 2.Relationships between CYP2B6 metabolizer genotype, NAT2 acetylator genotype, and plasma nevirapine concentrations among 35 nevirapine group participants.

Each panel indicates which CYP2B6 metabolizer genotype and NAT2 acetylator genotype is represented. The percentages in each panel represent individuals in whom nevirapine concentrations increased from baseline (week 0) to week 2. Red lines and markers represent individuals in whom nevirapine concentrations increased from baseline to week 2. Note that Y-axes differ among the graphs. The graphs only include individual who also had data for sex, and nevirapine concentration data between 10 hours and 15 hours post dose. NVP = nevirapine.

Pharmacogenetic Interactions of Rifapentine plus Isoniazid with Efavirenz or Nevirapine

Pharmacogenet Genomics. ;31(1):17-27.
Fig. 3

To investigate the oral bioavailability of nevirapine SEDDS, the pharmacokinetic parameters of nevirapine were determined after oral administration of nevirapine SEDDS and marketed conventional suspension to male Wistar rats. shows the change of mean plasma concentration after oral administration of nevirapine in rats. The calculated relative bioavailability of the nevirapine SEDDS compared to the marketed suspension was 269%. The AUC_0-t of nevirapine from SEDDS was found to be significantly higher (P<0.05) as compared to marketed conventional suspension. The K_ele and t_1/2 values of nevirapine from SEDDS were not much different from suspension. The C_max of the SEDDS was much higher than the suspension ().

In vivo Evaluation of Self Emulsifying Drug Delivery System for Oral Delivery of Nevirapine

Indian J Pharm Sci. 2014 May-Jun;76(3):218-224.
Fig. 2

DSC thermograms.
DSC thermograms of a, pure nevirapine; b, nevirapine formulation with HPMC; and c, nevirapine formulation with Lutrol F127.

Preparation and Characterisation of Nevirapine Oral Nanosuspensions

Indian J Pharm Sci. 2014 Jan-Feb;76(1):62-71.
Figure 5Relationship between nevirapine trough concentration and underlying liver diseases.

The differences for nevirapine trough concentration between lead-in and steady-state periods was observed in patients with HBV infection (A). The nevirapine trough concentration at week 4 was significantly lower than the values at week 24, 36 and 48 (P<0.05) in patients with HCV infection (B). The nevirapine trough concentration at week 48 in patients with HCV infection was significant higher than those without HCV coinfection (P = 0.004).

Comparison of Nevirapine Plasma Concentrations between Lead-In and Steady-State Periods in Chinese HIV-Infected Patients

PLoS One. 2013;8(1):e52950.